A carregar...

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

(1) Background: Bevacizumab-based regimens are a standard treatment for metastatic colorectal cancer (mCRC) patients, however meaningful clinical biomarkers for treatment benefit remain scarce. (2) Methods: Tumor samples from 36 mCRC patients treated with bevacizumab-based chemotherapy underwent com...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Hsu, Hung-Chih, You, Jeng-Fu, Chen, Shu-Jen, Chen, Hua-Chien, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Yang, Tsai-Sheng, Lapke, Nina, Tan, Kien Thiam
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721375/
https://ncbi.nlm.nih.gov/pubmed/31366114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11081079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!